Femasys

Femasys is an Atlanta, Georgia-based biomedical company developing and commercializing office-based fertility and non-surgical permanent birth control technologies for women. The lead product FemBloc is a non-surgical permanent contraceptive system designed for in-office delivery, paired with the FemaSeed intrauterine insemination product for infertility treatment. The company is led by founder and CEO Kathy Lee-Sepsick and trades on Nasdaq under the symbol FEMY. Femasys executed a 1-for-20 reverse stock split effective June 5, 2026 and regained Nasdaq minimum-bid compliance on June 23, 2026 after its closing bid held at or above $1.00 for 10 consecutive business days. The company had previously received a 180-day Nasdaq extension in January 2026 to address the listing-qualification deficiency triggered by sub-$1.00 closes in 2025.